AIMS On the basis of the JUPITER trial, European health authorities recently approved the use of rosuvastatin to reduce first major cardiovascular events among 'high' global risk primary prevention patients defined either by Framingham risk score >20% or European systematic coronary risk evaluation (SCORE) ≥5%. However, as these are post hoc analyses, data describing these subgroups have not pr...

INTRODUCTION AND OBJECTIVES The sensitivity of cardiovascular risk functions is low because many cardiovascular events occur in low- or intermediate-risk patients. The aim of the present study was to evaluate how the ankle-brachial index (ABI) reclassifies these patients. METHODS We conducted a descriptive, transversal, multicenter study (28 centers) of 3171 randomly selected patients aged >4...

BACKGROUND Psoriasis is a chronic inflammatory disease and its pathogenesis involves an interaction between genetic, environmental, and immunological factors. Recent studies have suggested that the chronic inflammatory nature of psoriasis may predispose to an association with other inflammatory diseases, especially cardiovascular diseases and metabolic disorders. OBJECTIVES To describe the de...

BACKGROUND Framingham-based and Reynolds Risk scores for cardiovascular disease (CVD) prediction have not been directly compared in an independent validation cohort. METHODS AND RESULTS We selected a case-cohort sample of the multiethnic Women's Health Initiative Observational Cohort, comprising 1722 cases of major CVD (752 myocardial infarctions, 754 ischemic strokes, and 216 other CVD death...

OBJECTIVE This study aims to examine the validity of the Framingham general cardiovascular disease (CVD) risk chart in a primary care setting. DESIGN This is a 10-year retrospective cohort study. SETTING A primary care clinic in a teaching hospital in Malaysia. PARTICIPANTS 967 patients' records were randomly selected from patients who were attending follow-up in the clinic. MAIN OUTCOM...